Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belagenpumatucel-l
- Development stage
- Phase 3
- Lead developer
- NovaRx
- Modality
- Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
Belagenpumatucel-l is a therapeutic cancer vaccine developed for the treatment of non-small cell lung cancer (NSCLC). It is prepared by transfecting allogeneic NSCLC cells with a plasmid containing an antisense transgene targeting transforming growth factor beta 2 (TGF-beta2), followed by expansion, irradiation, and freezing of the cells. Upon administration, this vaccine aims to elicit a cytotoxic T lymphocyte response against host NSCLC cells and suppress tumor-derived TGF-beta2 production, thereby enhancing immunogenicity and reducing tumor proliferation. The drug was primarily developed as maintenance therapy for advanced NSCLC but has also been investigated in glioma. Its mechanism involves both immunostimulation and inhibition of transforming growth factor beta signaling[1][3][5][8].
- Brand names
- Lucanix
- Other names
- GlionixRanagengliotucel-T
02
Targets
TGFB2 (Transforming growth factor beta 2)
Beyond the preview
Go deeper on belagenpumatucel-l.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belagenpumatucel-l.